DNTH Hedge Fund Ownership (Q2 2026)

Dianthus Therapeutics Inc (DNTH)

261 + Investors. Track Smart Money conviction in DNTH. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — DNTH

Based on 265 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 8 quarters in a row

last 6Q

For 8 consecutive quarters, more hedge funds added DNTH than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

265 hedge funds hold DNTH right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +157% more funds vs a year ago

fund count last 6Q

+162 new funds entered over the past year (+157% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 63% buying

180 buying106 selling

Last quarter: 180 funds were net buyers (62 opened a brand new position + 118 added to an existing one). Only 106 were sellers (68 trimmed + 38 sold completely). A clear majority buying is a strong confirmation signal.

⚠️

Fewer new buyers each quarter (-33 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 52 → 47 → 95 → 62. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔄

Mostly new holders — 53% entered in last year

■ 18% conviction (2yr+) ■ 28% medium ■ 53% new

Only 49 funds (18%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

🚀

Acceleration phase — new buyers rushing in

18 → 52 → 47 → 95 → 62 new funds/Q

New funds entering each quarter: 52 → 47 → 95 → 62. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🌱

Early stage — 62% of holders entered in last year

■ 21% veterans ■ 17% 1-2yr ■ 62% new

Of 271 current holders: 167 (62%) entered in the past year, only 57 (21%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

🏆

Elite ownership — 50% AUM from top-100 funds

50% from top-100 AUM funds

54 of 263 holders are among the 100 largest funds by AUM, controlling 50% of total institutional value in DNTH. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

6.0

out of 10

Moderate Exit Risk

Exit risk score 6.0/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	261	241	8.3%
13F Shares	66M	63M	5.62%
Total Value	$5.75B	$4.99B	15.3%
New Positions	61	95	-34
Increased Positions	113	83	+30
Closed Positions	39	21	+18
Reduced Positions	68	54	+14
Total Calls	4	5	-20.0%
Total Puts	4	5	-20.0%
PUT/CALL Ratio	1.0	1.0	Neutral

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

261

241

8.3%

13F Shares

66M

63M

5.62%

Total Value

$5.75B

$4.99B

15.3%

New Positions

-34

Increased Positions

113

+30

Closed Positions

+18

Reduced Positions

+14

Total Calls

-20.0%

Total Puts

-20.0%

PUT/CALL Ratio

1.0

Neutral

Institutional Holders (2026 Q2)

261 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in DNTH. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 DNTH holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Avidity Partners Management LP	32.85%	2,104,184	$205.1M
2	Fairmount Funds Management LLC	16.35%	2,537,191	$247.3M
3	Octagon Capital Advisors LP	16.14%	1,841,667	$179.5M
4	Spruce Street Capital LP	6.79%	354,816	$34.6M
5	Silverarc Capital Management, LLC	3.95%	390,000	$38.0M
6	TCG Crossover Management, LLC	3.93%	1,676,624	$163.4M
7	Cormorant Asset Management, LP	3.75%	750,000	$73.1M
8	Venrock Adviser, LLC	3.49%	1,180,000	$115.0M
9	Stempoint Capital LP	3.37%	200,851	$19.6M
10	Logos Global Management LP	3.36%	800,000	$78.0M
11	Vivo Capital, LLC	3.15%	353,998	$34.5M
12	First Turn Management, LLC	2.98%	285,771	$27.9M
13	Artia Global Partners LP	2.93%	162,990	$15.9M
14	MPM BioImpact LLC	2.50%	420,002	$40.9M
15	Braidwell LP	2.14%	594,562	$58.0M
16	Eagle Health Investments LP	2.12%	131,344	$12.8M
17	Bain Capital Life Sciences Investors, LLC	2.10%	362,470	$35.3M
18	Affinity Asset Advisors, LLC	1.76%	400,000	$39.0M
19	Patient Square Capital LP	1.63%	108,000	$10.5M
20	Tri Locum Partners LP	1.45%	120,712	$11.8M
21	Moody Aldrich Partners LLC	1.31%	74,552	$7.3M
22	Jones Hill Capital LP	1.18%	57,100	$5.6M
23	Tang Capital Management LLC	1.17%	264,692	$25.8M
24	Deerfield Management Company, L.P.	1.14%	1,125,313	$109.7M
25	HighVista Strategies LLC	1.14%	51,125	$5.0M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Dianthus Therapeutics Inc (DNTH)

What does the Smart Money Trend signal show for DNTH?

Buying streak — 8 quarters in a row: For 8 consecutive quarters, more hedge funds added DNTH than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for DNTH?

More buyers than sellers — 63% buying: Last quarter: 180 funds were net buyers (62 opened a brand new position + 118 added to an existing one). Only 106 were sellers (68 trimmed + 38 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for DNTH holders?

Elite ownership — 50% AUM from top-100 funds: 54 of 263 holders are among the 100 largest funds by AUM, controlling 50% of total institutional value in DNTH. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held DNTH?

Mostly new holders — 53% entered in last year: Only 49 funds (18%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Dianthus Therapeutics Inc (DNTH)

Smart Money Signals — DNTH

Buying streak — 8 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +157% more funds vs a year ago

More buyers than sellers — 63% buying

Fewer new buyers each quarter (-33 vs last Q)

Mostly new holders — 53% entered in last year

Acceleration phase — new buyers rushing in

Early stage — 62% of holders entered in last year

Elite ownership — 50% AUM from top-100 funds

Institutional Sentiment Summary — DNTH

Hedge Fund Ownership: DNTH

Market Analysis: DNTH

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: DNTH

Hedge Fund Positioning: DNTH

Statistics: DNTH

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Dianthus Therapeutics Inc (DNTH)

Welcome to 13Foresight!